NCT03994107 - Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

January 1, 2021

Study Completion Date

January 1, 2021

Conditions

Breast Cancer

Interventions

DRUG

Pegylated Liposomal Doxorubicin

"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."

DRUG

Albumin-bound paclitaxel

220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.

DRUG

Trastuzumab

8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.

Trial Locations (1)

RECRUITING

Fei Ma, Beijing